Clinical trials: copd or chronic obstructive
Pulmonary Disease, Chronic Obstructive
Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE]
The primary objective of this pragmatic study is to compare the time to first moderate or severe COPD exacerbation in patients, not controlled on their current therapy, randomized to Stiolto Respimat versus triple therapy over 12…
- Trial name
- NCT03265145
- Testing
- Stiolto Respimat, ICS (Inhaled Corticosteroid) (Triple therapy), LABA (Long-Acting Beta Agonist) (Triple therapy)
- Where
- 90 sites in United States
- Volunteers
- 714 people
- Sponsor
- Boehringer Ingelheim
COPD
Assessment of Switching From Salmeterol/Fluticasone to Indacaterol/Glycopyrronium in a symtomaticCOPD Patient Cohort
This study will investigate whether switching symptomatic COPD patients from a fixed-dose combination of salmeterol/fluticasone 50/500 µg b.i.d. to a fixed dose combination of QVA149 110/50 µg o.d.
- Trial name
- FLASH (NCT02516592)
- Testing
- QVA149 110/50 micrograms, Salmeterol/fluticasone 50/500 microgrammes
- Where
- 64 sites in Australia, Egypt and 9 more
- Volunteers
- 500 people
- Sponsor
- Novartis Pharmaceuticals
Cardiac Decompensation
Evaluate Heart Failure Patients With Specially Designed Patient Adherence and Monitoring Software on Standard Mobile Devices
This is planned as a feasibility study. The objective is to evaluate a specially designed patient adherence and monitoring software on standard mobile devices in remote monitoring of heart failure patients.
- Trial name
- REMOTE-HF-1 (NCT01430936)
- Where
- 5 sites in United States, India and 1 more
- Volunteers
- 51 people
- Sponsor
- Aventyn, Inc.
Chronic Obstructive Pulmonary Disease
Study of the Effect of the ROX AC1 on Exercise Capacity and Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients
To demonstrate the efficacy of ROX AC1 (with respect to exercise capacity and quality of life) in patients with COPD.
- Trial name
- NCT00832611
- Testing
- Arteriovenous Fistula (ROX AC1)
- Where
- Germany
- Volunteers
- 46 people
- Sponsor
- ROX Medical, Inc.
COPD, Healthy Volunteers
Airvo 3 Respiratory Rate Validation Study
This is a clinical performance testing to validate the accuracy of the Airvo 3 device with respiratory rate algorithm manufactured by Fisher \& Paykel Healthcare for continuous respiratory rate monitoring.
- Trial name
- NCT06329609
- Testing
- Airvo 3 with respiratory rate algorithm
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fisher and Paykel Healthcare
Chronic Obstructive Pulmonary Disease
A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).
This study will investigate the effect of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) metered dose inhaler (MDI) compared with Placebo MDI, and Budesonide and Formoterol Fumarate (BFF) MDI on isotime inspiratory…
- Trial name
- ATHLOS (NCT06067828)
- Testing
- Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate, Treatment B: Budesonide and Formoterol Fumarate
- Where
- 33 sites in United States, Canada and 5 more
- Volunteers
- 171 people
- Sponsor
- AstraZeneca
COPD
Predictive Questionnaires for Risk of Acute COPD (Chronic Obstructive Pulmonary Disease) Exacerbations
COPD patients frequently suffer intermittent exacerbations of their disease characterised by acute deterioration of symptoms. Acute exacerbations of COPD (AECOPD) are associated with significant impairment of health status, use…
- Trial name
- NCT01248507
- Where
- Spain
- Volunteers
- 634 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Efficacy Safety Study of Arformoterol QD Dosing Versus BID Dosing in COPD
To evaluate the efficacy and safety of arformoterol tartrate inhalation solution 30μg/4mL QD (two 15μg/2mL dosed in combination) over a 24-hour period compared to arformoterol tartrate inhalation solution 15μg/2 mL BID in…
- Trial name
- NCT00571428
- Testing
- Arformoterol Tartrate Inhalation Solution
- Where
- 4 sites in United States
- Volunteers
- 33 people
- Sponsor
- Sumitomo Pharma America, Inc.
Asthma, Bronchospasm
Dose-Ranging Study of A006 DPI, in Adult Asthma Patients
This study is a randomized, active- and placebo-controlled, single-dose, seven-arm, crossover and dose-ranging design. This study aims to evaluate the efficacy and initial safety profiles, and to identify the optimum dose of…
- Trial name
- NCT01174732
- Testing
- albuterol inhalation powder, albuterol inhalation aerosol
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Previously Treated PH + CML
Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors
The purpose of this study is to fulfill the post-authorization commitment made by Pfizer to the European Medicines Agency in providing additional safety and efficacy data in approximately 150 Philadelphia Chromosome Positive…
- Trial name
- NCT02228382
- Testing
- Bosutinib
- Where
- 48 sites in United States, Austria and 6 more
- Volunteers
- 163 people
- Sponsor
- Pfizer
COPD
Long-term Observational Study of the Safety of Roflumilast
This is a retrospective cohort study comparing COPD patients aged 40 years and older with new exposure to roflumilast with up to 5 unexposed (ie, not roflumilast-exposed) COPD controls matched by propensity score (PS), age, sex…
- Trial name
- NCT03381573
- Testing
- Roflumilast
- Where
- 4 sites in United States, Germany and 2 more
- Volunteers
- 135,856 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Study to Evaluate Efficacy and Safety of Inhaled BEA 2180 BR in COPD Patients
Study to investigate the dose-dependent bronchodilator effect and the safety of single inhalation doses of BEA 2180 inhaled via Respimat® compared to placebo in patients with stable Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT02242279
- Testing
- BEA 2180 BR, Tiotropium
- Volunteers
- 37 people
- Sponsor
- Boehringer Ingelheim
Wounds
Trial of PICO Versus Standard Care in Chronic and Sub-acute Wounds
Randomised Controlled Trial of PICO (a portable Negative Pressure Wound Therapy) versus standard care in patients with chronic and sub-acute wounds.
- Trial name
- NCT02458859
- Testing
- PICO (single use portable negative pressure wound therapy)
- Where
- 20 sites in Canada, United Kingdom
- Volunteers
- 62 people
- Sponsor
- Smith & Nephew, Inc.
Pulmonary Disease, Chronic Obstructive
A Phase 2 Study of the Safety and Efficacy of a Tofimilast in Adult Patients With Chronic Obstructive Pulmonary Disease
This an initial proof of concept, phase to study to assess the safety and efficacy of tofimilast for the chronic maintenance treatment of adults with Chronic Obstructive Pulmonary Disease
- Trial name
- NCT00219622
- Testing
- tofimilast
- Where
- 40 sites in United States, Argentina and 4 more
- Volunteers
- 300 people
- Sponsor
- Pfizer
Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis
Indacaterol EfectIveness In COPD Patients With Tuberculosis History
This clinical study will assess efficacy and safety of indacaterol (150㎍ o.d.) in patients with Chronic Obstructive Pulmonary Disease (COPD) with destroyed lung by tuberculosis.
- Trial name
- INFINITY (NCT01778062)
- Testing
- Indacaterol, Control
- Where
- 13 sites in South Korea
- Volunteers
- 136 people
- Sponsor
- Novartis Pharmaceuticals
Non-Invasive Ventilation
Wearable Noninvasive Positive Pressure Ventilation Device in COPD
The objective is to assess the impact of a wearable Noninvasive Positive Pressure Ventilation, on physical activity and quality of life in patients with severe COPD, complaining of dyspnea.
- Trial name
- VITABREATH (NCT03130361)
- Testing
- Non-Invasive Ventilation
- Where
- 7 sites in France
- Volunteers
- 40 people
- Sponsor
- Icadom
Chronic Bronchitis
A Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil In the Treatment of Chronic Bronchitis
Identifying the role of antibiotics in the treatment of subjects with a microbiologically documented acute exacerbation of chronic bronchitis (AECB) is the purpose of this clinical trial.
- Trial name
- NCT00255983
- Testing
- Faropenem medoxomil
- Where
- United States
- Volunteers
- 491 people
- Sponsor
- Replidyne
Pulmonary Disease, Chronic Obstructive
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease
The purpose of this study is to evaluate the 24-hour spirometry effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg once daily compared with tiotropium bromide inhalation powder 18mcg once daily over a…
- Trial name
- NCT01627327
- Testing
- fluticasone furoate/vilanterol 100/25mcg, tiotropium bromide 18mcg
- Where
- 54 sites in United States, Canada and 4 more
- Volunteers
- 623 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety Comparison of Steroid or Placebo in Combination With Salmeterol and Tiotropium in COPD
This efficacy and safety study compares four different combinations of blinded inhaled steroid treatments on top of open-label tiotropium and salmeterol in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00535366
- Testing
- Tiotropium, Salmeterol, Fluticasone
- Where
- 12 sites in Belgium, Denmark and 2 more
- Volunteers
- 103 people
- Sponsor
- Boehringer Ingelheim
COPD, Chronic Obstructive Pulmonary Disease
A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease
The purpose of this study is to evaluate the dose-response of different doses of CHF 5259 pMDI on lung function and other clinical outcomes, to identify the optimal dose(s) in terms of benefit/ risk ratio for further development…
- Trial name
- GLIMMER (NCT03084796)
- Testing
- CHF 5259, Tiotropium Bromide 18 µg Inhalation Capsule
- Where
- 112 sites in United States
- Volunteers
- 733 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.